<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
Blogs

CU Cancer Center News and Stories

Diversity

Diversity    Magazine

Director's Message: Our Commitment to Dismantling Racism

The past year has illuminated the need for change. In addition to the toll it has taken on lives, health and livelihood, COVID-19 has shed light on health disparities and inequities facing our communities of color.


Author Cancer Center | Publish Date December 03, 2020
Full Story

Pediatric Cancer    Brain and Spinal Cancer    Diversity

Post-diagnosis disparities drive poorer outcomes for pediatric Black and Hispanic brain cancer patients

Cancer researchers have known for years that Black and Hispanic patients have worse outcomes than their non-Hispanic White peers. At least when it comes to adults. But few studies have explored these same disparities in pediatric patients, and fewer still have looked for racial/ethnic differences in treatment outcomes in pediatric brain cancer patients.


Author Cancer Center | Publish Date March 12, 2020
Full Story

Lung Cancer    Diversity

African Americans, Hispanics less likely to receive recommended lung cancer imaging

The use of PET-CT imaging gives doctors the best possible picture of non-small cell lung cancer (NSCLC), and this accurate imaging helps to match patients with the best treatments. Unfortunately, not every NSCLC patient gets the recommended PET-CT imaging. Now a University of Colorado Cancer Center study published in the Journal of the National Cancer Institute shows an important predictor of PET-CT use: African American patients were only about half as likely as non-Hispanic whites to receive this important imaging; Hispanics received this imaging about 70 percent as frequently as non-Hispanic whites.


Author Cancer Center | Publish Date March 11, 2020
Full Story

Diversity    Cancer    Genetics

The genetic diversity that may explain differences in cancer rates across ethnicities

Paul Norman, PhD, was born in the Midlands region of Central England in the county town of Shrewsbury, which, coincidentally, is also the birthplace of the naturalist and explorer, Charles Darwin. And like Darwin, Norman set out on a mission to categorize the diversity of life. Only, while Darwin concerned himself with things he could see – the beak shape of Galapagos finches, for example – Norman explores the diversity of cells hidden inside our bodies. Even more specifically, Norman, who recently joined University of Colorado Cancer Center as a mentored member, researches the diversity of tiny proteins that sit on the surface cancer cells. What seems little could be very big: Differences in these proteins across ethnicities could help to explain the differences in cancer rates between human cultures. 


Author Cancer Center | Publish Date May 13, 2019
Full Story

CU Cancer Center In the News

5280

No, Sun Exposure Is Not the Secret to Living Longer (Probably)

news outlet5280
Publish DateJanuary 05, 2022

CU Cancer Center member Neil Box, MD, separates fact from pseudoscience when it comes to protecting yourself from the sun.

Full Story
Denver 7

'I'm Just so Proud of Him': Crested Butte Family Shares 2-year-old's Journey with Kidney Cancer

news outletDenver 7
Publish DateDecember 23, 2021

In 2021, a Crested Butte family received a life-changing diagnosis. During the holiday season, their story is an apparent reminder that sometimes the best gifts are never found under a tree.

Full Story
Cure Today

Triplet Regimen Extends Time Before Brain, Spinal Cord Metastases Worsen in Patients with Breast Cancer

news outletCure Today
Publish DateDecember 15, 2021

A three-drug regimen was shown to lengthen the amount of time before cancer progressed to the central nervous system — known as central nervous system progression-free survival — in certain patients with breast cancer.

Full Story
Healio

Liso-cel Significantly Improves Outcomes in Second-Line DLBCL

news outletHealio
Publish DateDecember 11, 2021

Second-line lisocabtagene maraleucel more than quadrupled EFS compared with standard therapy for patients with relapsed or refractory large B-cell lymphoma, according to study results presented at ASH Annual Meeting and Exposition.

Full Story